Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Iovance Biotherapeutics (IOVA) over the last 7 years, with Q3 2025 value amounting to -$4.4 million.

  • Iovance Biotherapeutics' Change in Account Payables fell 13043.09% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year decrease of 17789.52%. This contributed to the annual value of -$7.8 million for FY2024, which is 26240.68% down from last year.
  • Per Iovance Biotherapeutics' latest filing, its Change in Account Payables stood at -$4.4 million for Q3 2025, which was down 13043.09% from $893000.0 recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Change in Account Payables peaked at $14.4 million during Q3 2024, and registered a low of -$10.4 million during Q2 2024.
  • Moreover, its 3-year median value for Change in Account Payables was $146000.0 (2023), whereas its average is -$405545.5.
  • The largest annual percentage gain for Iovance Biotherapeutics' Change in Account Payables in the last 5 years was 24781.9% (2024), contrasted with its biggest fall of 721643.84% (2024).
  • Iovance Biotherapeutics' Change in Account Payables (Quarter) stood at $11.4 million in 2023, then crashed by 153.16% to -$6.1 million in 2024, then rose by 27.65% to -$4.4 million in 2025.
  • Its Change in Account Payables stands at -$4.4 million for Q3 2025, versus $893000.0 for Q2 2025 and $2.1 million for Q1 2025.